Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Trinity Research & Innovation-Licensing Opportunity A E
Document related concepts
Transcript
TRINITY COLLEGE DUBLIN Trinity Research & Innovation-Licensing Opportunity AN EFFICIENT CATALYST A novel catalyst for the production of enantiomer specific pregabalin. Technology Overview Progablin is a blockbuster anticonvulsat drug, marketed as Lyrica, used to treat neuralgiac pain. A difficulty in its synthesis is ensuring that the right chiral enantiomer is formed. Trinity researchers have developed a new method to selectively synthesise the appropriate enatiomer of an immediate precursor to the drug using a highly efficient catalyst. The product yields and ‘enantio-selectiveness’ of the new process are uniformly excellent and the catalyst can be used under very mild and scalable conditions. Advantages: Development Stage: The synthesis of ‘enantiopure’ pregabalin has the requirement for a step which discards 50% of the product which is inefficient and wasteful. The technology on offer here modifies the synthesis process to preferentially create the desired enantiomer. The catalyst has been reduced to practice and the efficiency of its enantiomer selectiveness is known. This invention is based on a desymmetrisation step – a meso starting material is converted to a chiral enantioenriched product in a highly selective manner. Thus the need for a costly resolution step has been removed. A patent application has been filed in Europe Other similar attempts to create a enanatiomer sensitive catalyst have proved impractical due to a requirement for large amounts of catalyst (quinine or quinidine) and the need for low reaction temperatures (50 and -78 °C). The catalyst presented here is efficient to the point where it can be used at low levels of 1-2 mol%. In addition this catalyst functions at ambient temperatures (or lower, if required). Principal Inventor(s): Dr. Stephen Connon, Aldo Peschiulli, Lyn Markey Patent: TCD Ref: SC01-181-01 Contact: Name: Graham McMullin, Ph.D Position: Technology Transfer Case Manager Tel: + 353 1 896-1711 Email: [email protected]
